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ehdi H. Shishehbor, DO, MPH,* Steven J. Filby, MD,* Adnan K. Chhatriwalla, MD,*
yan D. Christofferson, MD,* Anil Jain, MD,†‡ Samir R. Kapadia, MD,*
. Michael Lincoff, MD,* Deepak L. Bhatt, MD,* Stephen G. Ellis, MD*
leveland, Ohio
bjectives Our aim was to assess the incidence of all-cause mortality in patients with anemia un-
ergoing percutaneous coronary intervention (PCI) receiving drug-eluting stents (DES) or bare-metal
tents (BMS).
ackground Anemia has been associated with poor clinical outcomes in patients undergoing PCI.
owever, it is unknown whether stent selection (DES or BMS) has a differential outcome in this
igh-risk group.
ethods Anemia was deﬁned as a hematocrit below 36% for female subjects and below 40% for
ale subjects as deﬁned by the World Health Organization. All patients undergoing PCI with DES or
MS alone from March 2003 to June 2007 were included. The primary end point was all-cause mor-
ality. Anemia was further characterized using mean corpuscular volume as microcytic, normocytic,
r macrocytic.
esults A total 11,181 patients underwent PCI over a 4.5-year interval; of these, 2,172 met our in-
lusion criteria. There were a total of 429 deaths. The majority of patients had normocytic anemia
n  1,931). Of the 3 anemia subtypes, macrocytic anemia (DES 26%, BMS 44%) had the highest
ortality followed by normocytic (DES 17%, BMS 25%) and microcytic (DES 13%, BMS 18%) anemia,
espectively. All-cause mortality was signiﬁcantly lower with DES in unadjusted and multivariable
djusted Cox proportional models (adjusted hazard ratio: 0.66, 95% conﬁdence interval: 0.54 to 0.82;
 0.001).
onclusions In an adjusted analysis, the use of DES as compared with the use of BMS was associ-
ted with decreased mortality in patients with anemia. Additionally, among anemia subtypes, mac-
ocytic anemia had the highest mortality. (J Am Coll Cardiol Intv 2009;2:329–36) © 2009 by the
merican College of Cardiology Foundation
rom the Department of *Cardiovascular Medicine, †Internal Medicine, and ‡Information Technology Division, Cleveland
linic, Cleveland, Ohio.anuscript received July 15, 2008; revised manuscript received November 18, 2008, accepted November 23, 2008.
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330nemia has been characterized as an independent cardio-
ascular risk factor; its presence portends poor outcomes in
atients with coronary artery disease. It is associated with
igher rates of in-hospital mortality in patients with con-
estive heart failure and myocardial infarction (MI), and
atients with pre-operative anemia have higher mortality
fter coronary artery bypass surgery (1–5). Importantly,
everal studies have also shown a strong association between
nemia and adverse clinical events in patients undergoing
ercutaneous coronary intervention (PCI) (6–8).
See page 337
Due to reports of increased incidence of stent thrombosis
ith drug-eluting stents (DES), a 1-year course of dual
ntiplatelet therapy with aspirin and a thienopyridine agent is
urrently recommended in DES-treated patients (9). The
resence of low hemoglobin is of particular concern in these
patients as they may be at in-
creased risk of bleeding during
this treatment period; and for this
reason, operators often choose to
place bare-metal stents (BMS) in
anemic patients. Still, there are no
available data regarding the im-
pact of stent selection (DES vs.
BMS) in anemic patients to guide
decision making during PCI. We,
thus, examined the incidence of
all-cause mortality in patients
with anemia undergoing PCI who
received DES versus BMS. Fur-
thermore, we examined the inter-
action between anemia subtype
and mortality in each stent group.
ethods
tudy population. Patients who underwent PCI between
arch 2003 to June 2007 at a single institution and received
nly DES or a BMS were identified through a query of the
nstitutional PCI registry. Briefly, baseline characteristics,
ardiac history, risk factors, medications, angiographic and
rocedural data were prospectively obtained and recorded.
e also accounted for variables that may be important in
electing a DES or BMS. These included depression,
alignancy, and socioeconomic status (SES). SES was
btained from U.S. census data using a validated score
10,11). The primary end point was all-cause mortality,
hich was assessed by querying the Social Security Death
ndex. The institutional review board waived requirements
or informed consent for the institutional PCI registry.
ngiographic data were collected on all patients undergoing
bbreviations
nd Acronyms
MS  bare-metal stent(s)
I  confidence interval
ES  drug-eluting stent(s)
CT  hematocrit
R  hazard ratio
CV  mean corpuscular
olume
I  myocardial infarction
CI  percutaneous
oronary intervention
ES  socioeconomic status
VR  target vessel
evascularizationCI and recorded in the cardiovascular information registry. oeﬁnition of anemia. Blood studies were routinely obtained
n all patients before PCI including white blood cell count,
erum hemoglobin, hematocrit (HCT), and creatinine.
aseline anemia was defined as an HCT 36% for female
ubjects and as an HCT 40% for all male subjects, in
ccordance with World Health Organization definition
12). We further categorized patients into the following
iers based on degree of anemia: HCT28, HCT 29 to 35,
nd HCT 35. In order to further delineate the impact of
tent selection in different subtypes of anemia, we used
ean corpuscular volume (MCV) and divided the cohort
nto subgroups with microcytic (MCV 80), normocytic
MCV 80 to 100), and macrocytic anemia (100) (13).
tatistical analysis. Continuous variables are presented as
ean  SD. Differences in baseline and angiographic
haracteristics were compared using the Wilcoxon rank sum
est for continuous variables and the chi-square test for
ategorical variables. We used Kaplan-Meier curves to
resent the unadjusted time-to-event data. Additionally,
ultivariable modeling was performed using Cox propor-
ional hazards method to examine the association between
he use of BMS and DES and all-cause mortality while
ccounting for the differences in baseline demographic
eatures, angiographic variables, and other confounders
hown in Tables 1 and 2. All statistical analyses were
erformed using SAS software, version 9.1 (SAS Inc., Cary,
orth Carolina) and S-plus 7.0 (Insightful, Inc., Seattle,
ashington). All tests were 2-tailed; a p value of0.05 was
onsidered significant.
esults
aseline characteristics. A total of 2,172 patients met our
tudy criteria; of these, 662 received only BMS and 1,510
nderwent stenting with only DES (Tables 1 and 2).
atients presenting with acute coronary syndromes were
ore likely to receive BMS (Table 1). Alternatively, DES
se was more common among patients with smaller mean
tent diameters, longer mean stent length, and longer mean
esion length (Table 2). Additionally, patients undergoing
ntervention for chronic total occlusions, in-stent restenosis,
nd multivessel disease were more likely to receive DES.
revalence of chronic conditions such as malignancy, kidney
isease, chronic obstructive lung disease, and peripheral
ascular disease was similar among patients receiving DES
nd BMS (Table 1).
tent type and degree of anemia. The majority of patients in
ur analysis had only mild anemia with 52% of those having
CT35 and 95% having HCT29. As shown in Figure 1,
ES use was more prevalent than BMS at each HCT tier, and
ven those patients in our study with the lowest HCT levels
ere more likely to receive DES than BMS.
ssociation of anemia with mortality. A total of 429 deaths
ccurred during the follow-up period. In a multivariable
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331odel despite adjusting for over 25 variables, HCT was
ignificantly associated with all-cause mortality (adjusted
azard ratio [HR]: 0.93, 95% confidence interval [CI]: 0.91
o 0.96; chi-square  27.4, p  0.001). In the multivariable
odel, despite adjusting for HCT as a continuous variable
nd all confounders shown in Table 1, macrocytic (adjusted
R: 2.05, 95% CI: 1.15 to 3.69; chi-square  5.9, p 
Table 1. Baseline Characteristics According to Stent Type
Characteristics
Bare-Meta
(n  6
Age, yrs 69
Male gender, % 71
Socioeconomic score 0.7
Body mass index, kg/m2 28.7
Heart rate, beats/min 73
Left ventricular ejection fraction, % 47
Malignancy, % 7
Depression, % 1
Risk factors, %
Diabetes, insulin dependent 18
Diabetes, noninsulin dependent 22
Family history of coronary artery disease 21
Current smoking 13
Blood markers
Hematocrit, % 34.3
Creatinine, mg/dl 1.5
White blood cell count, k/l 8.2
Medical history, %
Prior myocardial infarction 52
Prior coronary bypass surgery 37
Peripheral arterial disease 25
Chronic obstructive pulmonary disease 21
Stroke or transient ischemic attack 14
New York Heart Association functional class, %
I 40
II 11
III 21
IV 16
Presentation, %
Acute myocardial infarction 11
Unstable angina 41
Medications on admission, %
Aspirin 92
Clopidogrel 100
Angiotensin-enzyme converting inhibitors 45
Beta-blockers 35
Statins 63
Heparin 50
Glycoprotein IIb/IIIa inhibitors 44
Classiﬁcation of anemia, %
Microcytic 8
Normocytic 86
Macrocytic 5.015) and normocytic anemia were significantly associated 1ith all-cause mortality (adjusted HR: 1.59, 95% CI: 1.04
o 2.45; chi-square  4.49, p  0.034) as compared with
icrocytic anemia.
nivariate and multivariable analysis. Mortality was high in
his cohort of patients with anemia undergoing PCI; how-
ver, patients treated with BMS had a significantly higher
ortality compared with those treated with DES (26% vs.
t Drug-Eluting Stent
(n  1,510) p Value
68 11 0.05
69 0.42
0.6 4.1 0.52
29.4 6.5 0.01
71 14 0.01
48 13 0.16
6.4 0.25
1.7 0.80
21.8 0.06
28.1 0.01
23.2 0.30
13.4 0.78
35.0 3.5 <0.01
1.4 1.2 0.76
8.2 15.7 0.60
52.0 0.70
38.6 0.57
21.6 0.07
16.4 0.01
15.5 0.38
35.6 0.05
14.8 0.06
20.3 0.53
17.9 0.38
6.1 0.01
45.4 0.11
92.0 0.62
100.0 1.00
45.0 0.90
32.4 0.16
72.2 0.01
40.9 0.01
38.4 0.01
6.8 0.16
90.1 0.01
3.1 0.01l Sten
62)
12
4.2
6.2
15
13
.7
.5
.3
.4
.2
.9
3.8
1.5
4.2
.9
.3
.1
.9
.0
.0
.8
.4
.3
.6
.7
.6
.0
.3
.5
.8
.4
.9
.5
.17%, p  0.001) for a median follow-up of 1.8 years (Fig.
2
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332). In both univariate and multivariable Cox proportional
azard analysis, DES use was associated with a 33% relative
isk reduction for all-cause mortality (adjusted HR: 0.66,
Figure 1. Percent DES or BMS Use According to Hematocrit Cutpoints
Table 2. Procedural Characteristics According to Stent Type
Characteristics
Bare-Meta
(n  6
Angiographic data, %
Number of diseased vessels
1 66.9
2 18.6
3 14.5
American College of Cardiology lesion type
A 5.1
B1 11.0
B2 46.2
C 37.6
Chronic total occlusions 2.7
Lesion location, %
Proximal left anterior descending 14.0
Mid or distal left anterior descending 40.6
Right coronary artery 37.0
Left circumﬂex artery 39.6
Procedural data
Lesion length, mm 14.0 
Reference diameter, mm 3.2 
Stent length, mm 23.8 
Graft intervention, % 16.2
Multivessel intervention, % 18.1
In-stent restenosis intervention, % 1.4
Procedural success, % 95.3Regardless of the hematocrit level, around 60% of the patients received a drug-eluti5% CI: 0.54 to 0.82; p  0.001). Additional subgroup
nalysis of patients with HCT 28 (adjusted HR: 0.69,
5% CI: 0.52 to 0.91; p  0.008); HCT 29 and 35
t Drug-Eluting Stent
(n  1,510) p Value
59.7 0.01
26.8 0.01
13.4 0.51
3.2 0.01
11.8 0.61
41.9 0.06
43.0 0.02
5.1 0.01
16.6 0.13
49.0 0.01
37.8 0.72
43.5 0.09
16.5  7.5 0.01
3.0  0.4 0.01
28.1  13.0 0.01
11.8 0.01
29.0 0.01
5.1 0.01
94.9 0.68l Sten
62)
6.8
0.7
12.1ng stent (DES) and 30% received a bare-metal stent (BMS).
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333adjusted HR: 0.58, 95% CI: 0.34 to 0.97; p  0.04); and
CT 35 (adjusted HR: 0.64, 95% CI: 0.45 to 0.91; p 
.01) yielded similar results (Fig. 3). Of anemia subtypes,
ormocytic anemia was most prevalent. Again, patients with
ormocytic anemia treated with DES had a lower mortality
han those treated with BMS (p  0.0001). Few patients
ad either microcytic or macrocytic anemia, though there
Figure 2. Kaplan-Meier Curves for DES Versus BMS in Patients With Anem
Notice the early separation and sustained mortality beneﬁt with DES. Abbrevia
Figure 3. Mortality According to Hematocrit Cutpoints
In univariate analysis, DES use was associated with lower mortality among tho
did not reach statistical signiﬁcance. Abbreviations as in Figure 1.as a trend favoring lower mortality in patients with
acrocytic anemia treated with DES (Fig. 4).
iscussion
he principal finding of this study is that treatment with
ES is associated with lower mortality than BMS in
as in Figure 1.
h hematocrit 29. This trend persisted for those with a hematocrit 28 butiase wit
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334atients with anemia. This treatment effect was indepen-
ent of baseline HCT, clinical and angiographic character-
stics, white blood cell count, serum creatinine, SES, and
resence of malignancy or depression. Reduced HCT was
ssociated with increased mortality in both BMS and DES
opulations, and those with the most profound anemia had
he highest mortality. Patients were more likely to receive
ES than BMS irrespective of HCT stratum or anemia
ubtype. In subgroup analysis, DES continued to be asso-
iated with lower mortality among those with lower HCT
alues and across different anemia subtypes. The results of
his analysis also indicate that, of the anemia subtypes,
atients with macrocytic anemia have the highest mortality.
There have been several recent studies suggesting that
atients with anemia undergoing PCI have poor cardiovas-
ular outcomes and increased mortality. In a study by
ikolsky et al. (14) of 6,929 post-PCI patients, low baseline
CT was independently associated with substantially
igher in-hospital and 1-year mortality rates. Another study
y Lee et al. (7) found pre-procedural anemia to be an
ndependent predictor of mortality that was associated with
igher short-term major adverse cardiac events in 6,116
onsecutive PCI patients. Taken together, these studies
ndicate that baseline anemia may be an independent
arker for future cardiovascular events and increased mor-
ality in patients undergoing PCI. Yet despite the reduction
n rates of target vessel revascularization (TVR) with the use
f DES as compared with BMS, some have raised concerns
ver the use of DES in at-risk populations such as those
ith anemia (15,16). Given the risk of bleeding with
Figure 4. Mortality According to Anemia Subclass
DES use was associated with lower mortality among those with macrocytic an
with microcytic anemia. Abbreviations as in Figure 1.ntiplatelet therapy and the recent recommendation for a arolonged course of dual antiplatelet therapy after DES
mplantation, these concerns take on even greater impor-
ance. However, to date the safety and efficacy of DES
ersus BMS in patients with anemia undergoing PCI has
ot been fully investigated.
To our knowledge, this is the first study to examine stent
ype and mortality in anemic patients. Surprisingly, DES
se was more prevalent than BMS in all anemic subgroups
n our analysis. One might have expected DES use to be
ower in this population due to concerns of increased risk of
leeding, especially with the prolonged thienopyridine
ourse currently recommended (9). Yet, as our study sug-
ests, those patients treated with DES had lower mortality
han those treated with BMS at every HCT stratum, thus
nderscoring the notion that DES may be used safely and
dvantageously in select anemic patients.
This mortality benefit of DES over BMS may seem
urprising in light of recent concerns of a possible increased
isk of death and MI from DES-related stent thrombosis
17–22), but, in fact, similar results of mortality reduction
ith DES have previously been reported in other popula-
ions. In a recent registry analysis, the use of DES was
ssociated with significant reductions in mortality, particu-
arly in high-risk patients (23,24). Consistent with these
ndings, recent studies have demonstrated that “off-label”
se of DES versus BMS is associated with lower adverse
ardiovascular outcomes and mortality (25–27). While no
andomized clinical trials to date have demonstrated a
ortality benefit with DES, these trials have largely focused
n lower risk populations and have excluded patients with
ocytic anemia. However, no signiﬁcant differences were noted among thosed normnemia. In contrast, our analysis, comprised entirely of
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335atients with anemia, demonstrates that DES-treated pa-
ients are much more likely to have high-risk angiographic
eatures. In addition, those who received DES were also
ore likely to be receiving PCI for “off-label” indications
uch as treatment of chronic total occlusions, in-stent
estenosis, or multivessel disease. However, despite the
otential mechanisms, selection bias and confounding may
till play a significant role in our findings. In addition, our
ohort has significant morbidity as shown in Table 1 and a
igher mortality compared with other studies that have
valuated PCI in the setting of anemia. Therefore, the
esults of our analysis may not be generalizable to all
atients with anemia.
The mechanism of the mortality benefit of DES over
MS was not directly examined in the present study. One
xplanation for our findings is that DES use lowers mor-
ality relative to BMS by preventing restenosis and lowering
ates of TVR. While some have suggested there may be an
ncreased risk of adverse events with DES from late stent
hrombosis, restenosis after BMS implantation is a much
ore common clinical problem, occurring in approximately
0% to 30% of patients (28,29). Though often presumed to
e a benign clinical entity, recent studies have indicated that
estenosis is sometimes associated with acute MI (30–32).
urthermore, TVR due to restenosis is also associated with
ncreased procedural complications such as death or MI
33). In this context, by preventing this common clinical
roblem and reducing the frequency of repeat intervention,
ES treatment may result in a mortality reduction that
ffsets the potential risk of DES-related adverse events. The
esulting net mortality benefit, however, may only be
resent in high-risk cohorts such as those with anemia and
igh-risk lesions. Additionally, it is possible that patients
reated with DES received longer courses of clopidogrel
han those treated with BMS. Prolonged treatment of
lopidogrel after PCI has been associated with reduced
ncidence of cardiovascular death and MI particularly in
igh-risk patients and could also have accounted for some of
he mortality benefit observed in this study (34).
To our knowledge, this is also the first study to examine
he impact of different subtypes of anemia on mortality in
atients undergoing PCI. Patients with a history of bleeding
vents are typically at highest risk of rebleeding with
nticoagulation and antiplatelet therapy during and after
oronary intervention. Blood loss can result in a normocytic
nemia, reflecting acute loss of blood cells along with blood
olume, or a microcytic anemia due to iron deficiency in
atients with chronic blood loss. Both of these subtypes had
etter outcomes than those with macrocytic indexes in our
tudy. However, normocytic and microcytic anemia have
any etiologies other than acute blood loss, and given that
cute bleeding is a contraindication to PCI, it is unlikely
hose in our study with normocytic or microcytic indexes
ad anemia from acute bleeding. While it is important tomphasize that DES use was associated with better out-
omes than BMS in every anemia subtype and HCT strata,
he results from the present study only apply to patients with
table pre-procedural anemia.
There are certain limitations of this study that should be
oted. First, this was an observational analysis and stent
ype (BMS vs. DES) was not randomized. Unmeasured
onfounding variables may have accounted for some of the
ifferences in outcomes, even though our analysis adjusted
or multiple potential confounding factors. Second, we are
nable to identify the exact etiology of anemia in each
atient. Although we divided patients based on MCV, it is
ell known that there can be considerable overlap as to the
tiology of anemia when using these cutoffs. In addition,
ome patients may have more than 1 type of co-existing
nemia yielding a mixed red blood cell index. Third, we did
ot have data on the incidence of bleeding and stent
hrombosis; therefore, we cannot comment on the risk of
ES on these important end points. Fourth, we did not
ave data regarding long-term clopidogrel use; however,
ost operators in our institution recommend clopidogrel
se for at least 1 year and in most cases indefinitely when
ES is used. Finally, few patients within the present
nalysis had severe anemia, and, thus, the results of our
tudy may only be applicable to patients with mild to
oderately low HCT levels.
onclusions
he use of DES as compared with BMS was independently
ssociated with lower mortality in patients with mild-to-
oderate, stable anemia undergoing PCI. While it is still
dvisable to treat patients at high risk for bleeding with
MS, the present study shows that the benefit of DES may
utweigh the risk in select anemic patients. However, we
emain cautious in advocating DES in all patients with
nemia due to the risk of selection bias and confounding
hat are associated with observational registries.
eprint requests and correspondence: Dr. Mehdi H. Shishe-
bor, Department of Cardiovascular Medicine, Cleveland
linic, 9500 Euclid Avenue, JJ40, Cleveland, Ohio 44195-
002. E-mail:shishem@gmail.com.
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